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1. Introduction 
Atherosclerosis is a complex, multifactorial disease, developed in the arterial wall in 
response to various forms of injurious stimuli, resulting in excessive inflammatory and 
fibro-proliferative reactions. The endothelial cells are involved in all stages of atherogenesis 
and their dysfunction is a key initial event in the atherosclerotic plaque formation 
(Simionescu, 2007). The vascular endothelium, with its broad spectrum of paracrine and 
autocrine functions, can be regarded as a multifunctional organ and “chief governor” of 
body homeostasis. Occupying a strategic location between the blood and tissues, the 
endothelial cells exist in a “high-risk position” and react progressively to aggressive factors, 
at first by modulation of the constitutive functions - permeability and biosynthesis 
(Simionescu & Antohe, 2006; Sima et al., 2009). Atherogenesis is an intricate process 
involving hyperlipidemia, oxidative stress and vascular inflammation. Among the diversity 
of mechanisms implicated in the pathogenesis of atherosclerotic vascular diseases two of 
them have been discovered in parallel and studied extensively: the oxidation of low-density 
lipoprotein (LDL) and the synthesis of endothelium-derived nitric oxide (NO). 
1.1 Relationship between oxidized LDL and NO as biomarkers of oxidative stress and 
endothelial dysfunction 
Oxidized LDL and NO are recognized to exert contradictory actions within the vascular 
endothelium microenvironment and to influence the key events in the development of 
atherosclerosis such as leukocyte adhesion, platelet aggregation and vascular smooth-
muscle cell proliferation and migration. While oxidized LDL (oxLDL) - a biomarker of 
lipoprotein-associated oxidative stress, is identified as a non-traditional pro-atherogenic 
emerging cardiovascular risk factor, NO is a free radical signal-transducing molecule that 
maintains the vasodilating tone, modulates in vitro lipid peroxidation reactions and alters 
proinflammatory gene expression (Figure 1). 
Endothelial dysfunction - known to precede the development of atherosclerosis, is a 
systemic pathological state of the endothelium defined as an imbalance between 
                                                 
* Corresponding author 
www.intechopen.com
  
Atherogenesis 
 
474 
vasodilating and vasoconstricting substances produced by (or acting on) the endothelium 
(Deanfield et al., 2007), leading to a reduced vasodilation, and even a proinflammatory and 
prothrombotic state (Cottone & Cerasola, 2008). 
The most important of the vasodilating substances is nitric oxide, characterized as a non-
eicosanoid component of endothelial-derived relaxation factor (EDRF), which is 
continuously synthesized by the endothelium under the action of different neurohumoral 
mediators such as acetylcholine, histamine, bradikinine, vasopressine, thrombine and 
serotonine (Rubbo et al., 1996).  
 
 
Fig. 1. Antiatherogenic effects and role of nitric oxide (NO) versus proatherogenic actions of 
oxidized LDL (oxLDL) exerted on vascular endothelium. 
NO is produced by a variety of mammalian cells including: vascular endothelial cells, 
neurons, smooth muscle cells, macrophages, neutrophils, platelets, cardiomyocytes and 
pulmonary epithelium. The family of three enzymes responsible for the synthesis of NO, 
nitric oxide synthases (NOSs): endothelial (eNOS), neuronal (nNOS), and inducible (iNOS) 
require calmodulin binding for their activities. The inducible nitric oxide synthases are 
transcriptionally regulated by cytokines and redox-sensitive transcriptional factors. Bacterial 
and parasitic antigens, which potently induce the expression of cytokines, also lead to 
induction of iNOS gene expression (Rubbo et al., 1996; Lundberg & Weitzberg, 2005). 
In the endothelial microenvironment, concurrently, a variety of substances that adversely 
influence endothelial function have been recognized, including free fatty acids, cytokines 
such as TNF-, and prooxidant molecules - including oxidized low-density lipoprotein 
(oxLDL). There are strong evidences for the role of oxidative stress in all stages of 
atherogenesis. Among different molecular targets affected by oxidative stress associated 
with hyperlipidemia and hyperglycemia, LDL is one of the most significant because is the 
major cholesterol carrier in the blood and contains also a relevant amount of 
polyunsaturated fatty acids (PUFAs) - the major substrate for lipid peroxidation.  
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The initial event in atherogenesis is the increased transcytosis of low-density lipoprotein, 
and its subsequent deposition, retention and oxidative modification in the subendothelium. 
It is followed by the infiltration of activated inflammatory cells from the coronary 
circulation into the arterial wall (Hulsmans & Holvoet, 2010).  
The oxLDL is a byproduct of exposure to reactive oxygen species (ROS), and several 
potential mechanisms have been proposed for LDL oxidation: cell-mediated lipoxygenase 
and myeloperoxidase activities, non-enzymatic metal ion-mediated oxidation (iron, copper), 
superoxide generators (xanthine oxidase, NADPH-oxidase), thiol-dependent oxidation, 
peroxynitrite and other radical generation compounds (Parthasarathy et al., 2008). 
Oxidatively modified lipoproteins lead to progression of atherosclerosis through 
macrophages engulfing oxLDL at the level of scavenger receptors, intracellular depositing of 
cholesterol esters and at last macrophages transformation into foam cells. Also,  oxLDL can 
induce an immune response leading to anti-oxLDL autoantibodies production, which will 
determine formation of immune complexes (Steinberg et al., 1989; Tsimikas & Witztum, 
2001; Parthasarathy et al., 1999, 2008).  
Endothelium relaxant factor is a central molecule in vascular homeostasis as a modulator of 
endothelial tone and reactivity, exerting pleiotropic positive effects on the cardiovascular 
system. Important for the cardiovascular biology is the consumption of NO by reactive 
oxygen species. Oxidative modification of NO not only leads to reduced bioavailability but 
also produces the toxic oxidant peroxynitrite (ONOO-), which further aggravates the 
imbalance of protective and aggressive factors (Cai & Harrison, 2000; Schnabel & 
Blankenberg, 2007). Subsequently, LDL oxidative modifications are made possible through 
simultaneous NO and superoxide anion radical (O2.-) actions.  
A key determinant of the pro-oxidant versus oxidant-protective influences of NO is the 
underlying oxidative status of tissue. When NO is in excess of surrounding oxidants, lipid 
oxidation and monocyte margination into the vascular wall are attenuated, producing 
antiatherogenic effects. However, when endogenous tissue rates of oxidant production are 
accelerated or when tissue oxidant defenses become depleted, NO gives rise to secondary 
oxidizing species that can increase membrane and lipoprotein lipid oxidation as well as 
foam cell formation in the vasculature, thus promoting proatherogenic effects (Bloodsworth 
et al., 2000). 
Therefore, targeting particularly upstream targets – substrates for oxidation and 
inflammation, will be important to better understand interactions of hyperlipidemia, 
inflammation and oxidation.  
Current evidence suggests that endothelial function is an integrative marker of the net 
effects of damage from traditional and emerging risk factors on the arterial wall and its 
intrinsic capacity for repair. This endothelial-dependent vascular biology is critical, not only 
in the initiation and progression of atherosclerosis, but also in the transition from a stable to 
an unstable disease state with attendant risks. As a result, study of endothelial function has 
emerged as an important endpoint in clinical research (Deanfield et al., 2007). 
1.2 Oxidized LDL and NO endothelial synthesis as factors affecting the vascular 
ageing 
Diseases of the vascular system have long been considered to be age-related in terms of their 
onset and progression. Longevity is a vascular question. More than 50 years ago, a famous 
anatomist – Rudolf Altschul stated that we have the age of our blood vessels: “a man is as 
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old as his arteries”. Senescent cells undergo distinct changes in gene expression that may 
cause an impairment of cellular function. In endothelial cells these changes result in a 
phenotype that is pro-inflammatory, pro-atherosclerotic, and prothrombotic. Endothelial 
cell senescence can be induced by a number of factors implicated in vascular pathologies, 
particularly by sustained cell replication and oxidative stress (Erusalimski, 2009). 
Oxidative stress and inflammation are major determinants of arterial and biological ageing. 
Recent studies underscore the association between white blood cell (WBC) telomere length, 
as index of systemic aging, oxidized LDL, and human vascular aging, expressed by the 
distensibility of the carotid artery. Results showed that higher levels of oxidized LDL are 
associated with shorter WBC telomeres and increased stiffness of the carotid artery (Nawrot 
& Staessen, 2008; Nawrot et al., 2010). 
Ageing is characterized not only by a reduced arterial compliance and alteration of the 
contractile properties of the vascular wall, but also by endothelial dysfunction (Alvarez de 
Sotomayor, et al., 2005; Brandes et al., 2006). At present, there are several reasons to believe 
that in vivo NO synthesis from L-arginine could indeed be impaired in atherosclerosis, 
hypertension, dyslipidemia, diabetes, obesity, insulin resistance, metabolic syndrome, as 
well as in ageing (Lind, 2002; Laroia et al., 2003; Hsueh & Quinones, 2003; Holvoet et al., 
2003, 2008a; Vickers et al., 2009; Park et al., 2009; Njajou et al., 2009; Huang, 2009; Park et al., 
2011; Tabit et al., 2010).  
Recent studies support the fact that advancing age increases the LDL susceptibility to 
oxidation and decreases the nitric oxide availability and bioactivity (Heffernan et al., 2008). 
Not only LDL but also very low-density lipoprotein (VLDL), beta–VLDL and even HDL 
undergo oxidative modification that must be taken into consideration in the complex 
process of atherosclerosis (Parthasarathy et al., 2008). In elderly, higher oxLDL levels were 
associated with high coronary risk before any clinical manifestation of CHD (Holvoet et al., 
2003), and with higher arterial stiffness, independent of cardiovascular disease risk factors 
(Brinkley et al., 2009). The oxLDL/Apo-B100 ratio and to a lesser extent the oxLDL/LDL-C 
ratio were significantly negative associated with the flow-mediated-dilation (FMD) of the 
brachial artery (van der Zwan et al., 2009). 
1.3 Methods for measuring the circulating oxidized LDL and NO endothelial synthesis 
Oxidative biomarkers are now showing strong associations with progression of coronary 
artery disease (CAD) and predict cardiovascular events, suggesting that they may serve as 
surrogates and may complement diagnostic investigations. Both in vitro and in vivo, low-
density lipoprotein (LDL) particles are susceptible to oxidation and peroxidation by all of the 
causes of oxidative stress. Therefore, oxidized LDL are included among the “downstream 
markers” of oxidative stress.  During the last decade, several monoclonal antibodies have been 
generated, each recognizing at least a substantial subset of the whole spectrum of oxLDL 
particles, leading to a myriad of new reports on the relation between circulating ox-LDL and 
cardiovascular pathological processes (Itabe and Ueda, 2007; Tsimikas, 2006).  
Currently used assays for oxLDL detect minimally oxidized LDL particles. In addition, 
concentrations of oxLDL depend on the sensitivity of LDL to oxidation; small dense LDLs 
contain smaller amounts of antioxidants and are, therefore, more prone to oxidation. The 
widely applied sensitive immunoassay quantifying the circulating levels of oxLDL uses a 
monoclonal antibody – 4E6, directed against oxidized apolipoprotein B-100 moiety of LDL 
(Rietzschel et al., 2008; Holvoet et al., 2008b).  
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The NO activity is assessed representatively using a variety of clinical invasive and 
noninvasive methods among which, the use of acetylcholine that induces endothelium-
dependent dilation and smooth muscle–mediated constriction. The coronary artery diameter 
is compared by quantitative angiography before and after infusion of acetylcholine. The 
functional status of the coronary microvasculature can also be assessed using intracoronary 
Doppler ultrasound to measure blood flow in resistance vessels in response to substances 
that produce either endothelial-dependent or endothelial-independent vasodilation. Another 
noninvasive method of detecting endothelial dysfunction uses high-resolution ultrasound to 
measure the brachial artery diameter in response to reactive hyperemia, which stimulates 
NO release and FMD (Davignon & Ganz, 2004). 
NO present in the circulation is originating from endothelial, smooth muscle cells, 
thrombocytes, leukocytes and cardiomiocytes. NO activity is the net result of a balance 
between its production and its inactivation by oxygen free radicals. NO released “in vivo” 
by nitric oxide synthase (NOS) activity in endothelial cells and platelets, rapidly 
autooxidizes to yield nitrite (NO2-), which interacts with oxyhemoglobin yielding nitrate 
(NO3-). Because nitrite plus nitrate are relatively stable compounds in blood, their levels 
may be a biochemical index of systemic NO production. This is convenient because direct in 
vivo measurements of NO can be very difficult due to the extremely low levels and its short 
half life. When combined measurements of nitrate and nitrite are conducted, this is usually 
denoted by the term NOx (Lundberg & Weitzberg, 2005; Hirata et al., 2010).  
2. Study on correlations of oxLDL and NOx with the metabolic profile in 
elderly with hyperlipidemia 
The LDL oxidation and nitric oxide are the key mediators involved in all stages of 
atherosclerosis: initiation, progression and complications. Their role is antagonistic: oxLDL 
have pro-atherogenic and NO antiatherogenic functions on vascular endothelium (Figure 1). 
A reduction in NO production or activity has been proposed as major mechanisms of 
endothelial dysfunction and a contributor to atherosclerosis. The endothelial dysfunction is 
considered an early marker for atherosclerosis and can be detected before structural changes 
in the vascular wall. An impairment of NO bioactivity or synthesis will reduce its braking 
effect on processes involved in atherogenesis. 
2.1 Purpose 
In the present study we evaluated the levels of circulating oxidized LDL (oxLDL) and the 
basal plasma levels of the NO metabolic pathway products, NOx (NO2- + NO3-), and 
examined their relationships with the global metabolic profile in a group of elderly patients 
with hyperlipidemia. We explored the determinants of oxLDL and NOx, as well as the 
relation between oxLDL and NOx in order to investigate whether the oxLDL/NOx and 
oxLDL/HDL-cholesterol ratios are more informative than the individual variables. 
2.2 Materials and methods 
2.2.1 Study design  
The study population included 170 subjects (72 men and 98 women) aged 60 - 70 years, of 
the patients hospitalized at the Ana Aslan- National Institute of Gerontology and Geriatrics 
(NIGG), Bucharest, Romania, who were selected according to clinical and biochemical 
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criteria. The subjects did not have diabetes or any liver, kidney, hematological or oncological 
overt diseases. We selected in a first group 125 subjects with a high cardiovascular risk lipid 
profile characterized by hypercholesterolemia [serum total cholesterol (TC) > 200 mg/dL 
and LDL-cholesterol (LDL-C) > 130 mg/dL], associated or not with hypertriglyceridemia 
[serum triglycerides (TG) < or > 150 mg/dL]. Subjects were not previously diagnosed with 
cardiovascular disease and were not under treatment with any vasoactive or cardiovascular 
drugs. None of the patients used lipid-lowering therapy or antioxidants. The second group 
considered as the control group included 45 apparently healthy subjects with normal lipid 
profile (TC < 200 mg/dL, LDL-C < 130 mg/dL and TG < 150 mg/dL). Anthropometric and 
clinical characteristics were collected after a complete clinical examination. All the 
participants in this study gave their written informed consent, and the study protocol was 
approved by the Ana Aslan - NIGG ethics committee. All the procedures followed were in 
accordance with the institutional guidelines. Venous blood samples were drawn after an 
overnight fast and 24-hours refraining from smoking, caffeinated foods and beverages. 
2.2.2 Biochemical methods 
Total cholesterol (TC), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), triglycerides 
(TG) and glycemia (G) were determinated by standard enzymatic methods. Results were 
expressed in mg/dL.  
The circulating plasma oxLDL was evaluated by a competitive ELISA kit with the 
monoclonal antibody 4E6 (kit 10-1158-01, Mercodia, Sweden) directed against an epitope in 
the apolipoprotein B-100 moiety of oxLDL, formed from substitution of lysine residues of 
apoB-100 with aldehydes (Holvoet et al., 2008). Results were expressed in U/L plasma. 
The total amount of plasma stable metabolic pathway products of NO, [NOx, the sum of 
nitrites and nitrates (NO2- + NO3-)] was determined using the Griess reagent, following the 
quantitative conversion of nitrates (NO3-) to nitrites (NO2-), with nitrate reductase (kit  
23479, SIGMA). Results were expressed in µmols NOx/L plasma. All the biochemical and 
immunoenzymatic tests were performed on a ChemWell 2190 Analyser (Awareness 
Technology, USA). 
The plasma atherogenic index (Ai) was calculated by the logarithmically transformed ratio of 
triglycerides on HDL-cholesterol (TG/HDL-C) (1) (Dobiasova, 2006; Dobiasova et al., 2011). 
 Ai = log(TG/HDL-C)  (1) 
2.2.3 Statistical analysis 
Data are expressed as meansSD. The subjects clinical characteristics were compared using 
the Mann Whitney Wilcoxon non-parametric test. Differences in means of studied 
parameters between the groups (hyperlipidemic vs. control group) were assessed by 
Student’s paired t test. The Pearson’s correlation test was used to perform bivariate 
correlation analysis. Multiple regression analysis was performed to evaluate the 
independent relation between studied parameters using the Statistical Package for Social 
Sciences software (SPSS) version 15. Significance was defined at the 0.05 level of confidence. 
2.3 Results 
The study population included 170 subjects aged 60-70 years. In order to establish the link of 
the traditional markers for the evaluation of the cardiovascular risk (TC, TG and LDL-C) at 
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systemic level with the oxidative stress and endothelial function parameters, patients were 
divided into two groups: a group with normal lipid profile (TC<200 mg/dL, LDL<130 
mg/dL, TG<150 mg/dL; n=45), and a group with high cardiovascular risk lipid profile  
(TC>200 mg/dL, LDL>130 mg/dL, TG < or > 150 mg/dL; n = 125).  
We firstly collected anthropometric data (body weight, height), clinical parameters, 
including systolic blood pressure, body mass index (BMI), fasting plasma glucose and the 
lipid profile in the two groups of our interest.  
Both cardiovascular disease risk and healthy control subjects showed not significantly 
different values of weight and body mass index, but systolic blood pressure, fasting plasma 
glucose and triglycerides were significantly higher in hyperlipidemic patients. The HDL-
cholesterol concentrations of the two groups were comparable. The atherogenic index and 
the TC /HDL-cholesterol ratio were significantly higher in hyperlipidemic group versus 
control (Table 1).  
Also, the increased lipid profile group had a significantly higher circulating levels of oxLDL 
associated with a significant decrease of the plasma nitric oxide metabolic pathway products 
(NOx) compared to the normolipidemic group (Table 1).  
 
Variables Control Group 
(n = 45) 
Hyperlipidemic 
Group 
(n = 125) 
Age (years) 653 664 
Sex (males/females) 15/30 55/70 
Systolic blood pressure (mmHg) 115.616.0 129.021.5** 
Diastolic blood pressure (mmHg) 74.69.7 73.512.7 
Body mass index (kg/m2 ) 22.52.9 23.25.3 
Glucose (mg/dL) 9112 10012** 
Total cholesterol (mg/dL) 18222 28532** 
Triglycerides (mg/dL) 7722 10348** 
LDL-cholesterol (mg/dL) 10524 21435** 
HDL-cholesterol (mg/dL) 5611 549 
Total cholesterol/HDL-C ratio 3.400.83 5.341.11** 
Atherogenic index (Ai) 0.130.15 0.240.19** 
Uric acid(mg/dL) 5.872.07 6.091.94 
oxLDL (U/L) 71.5113.11 85.5020** 
NOx (µmol/L) 32.5210.63 23.528.66** 
oxLDL/HDL cholesterol ratio 1.350.46 1.620.58* 
oxLDL/NOx ratio 2.440.92 4.131.87** 
Values are expressed as meansstandard deviation LDL, low-density lipoprotein; HDL-C high-density 
lipoprotein cholesterol; oxLDL, oxidized low-density lipoprotein; NOx,  nitric oxide metabolic pathway 
products * p values derived from Student t test: significantly different vs. control group;  
* p < 0.01;  ** p < 0.001 
Table 1. Clinical characteristics and metabolic variables in control and hyperlipidemic subjects.  
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To establish which variables other than LDL-C and NO were independent determinants of 
oxLDL and NO, we explored multiple linear regression models with oxLDL, NOx, 
oxLDL/HDL-C ratio and oxLDL/NOx ratio, as dependent variables, in control, 
hyperlipidemia, and whole study population. The results are presented in Table 2 and 3 and 
Figures 3-6. 
In multiple regression analysis for estimating the association between the degree of 
endothelial dysfunction and metabolic parameters, we found different statistically 
significant correlations within the two study groups. Tables 2 and 3 show the correlations of 
oxLDL and NOx with serum metabolic variables, atherogenic markers and indices in 
normal and hyperlipidemic subjects.  
In the control group (table 2) circulating oxLDL level positively correlated with glycemia 
and triglycerides, as well as the total cholesterol/HDL-cholesterol ratio.  
In subjects with high cardio-vascular risk (table 3) significant positive correlations between 
oxLDL and LDL-cholesterol were pointed out. In both study groups oxLDL was 
significantly negative correlated with HDL-cholesterol, and significantly positive with the 
atherogenic index (Ai).  
 
Variables oxLDL 
oxLDL/HDL-C 
ratio 
NOx 
oxLDL/NOx 
ratio 
Control Group (n = 45) 
Glucose (mg/dL) 0.351* 0.273 (NS) 0.164 (NS) - 0.004 (NS) 
Total cholesterol 
(mg/dL) 
0.257 (NS) - 0.470** - 0.088 (NS) 0.097 (NS) 
Triglycerides (mg/dL) 0.358* 0.273 (NS) - 0.259 (NS) 0.414** 
LDL-cholesterol 
(mg/dL) 
0.257 (NS) 0.396** - 0.024 (NS) 0.031 (NS) 
HDL-cholesterol 
(mg/dL) 
- 0.471** - 0.832** 0.081 (NS) - 0.291 (NS) 
Total cholesterol/HDL-
C 
0.528** 0.537** - 0.075 (NS) 0.252 (NS) 
Atherogenic index (Ai)  0.502** 0.605** - 0.267 (NS) 0.234** 
Uric acid(mg/dL) 0.200 (NS) 0.063 (NS) 0.184 (NS) - 0.045 (NS) 
oxLDL (U/L)  0.850** 0.074 (NS) 0.404** 
oxLDL/HDL-C ratio 0.850**  0.045 (NS) 0.357* 
NOx (µmol/L) 0.074 (NS) 0.045 (NS)  - 0.826** 
oxLDL/NOx ratio 0.404** 0.357* - 0.826**  
LDL, low-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; oxLDL, oxidized low-
density lipoprotein; NOx,  nitric oxide metabolic pathway products  
* p < 0.05; ** p < 0.01; NS, non-significant 
Table 2. Interrelationships between studied markers of lipoxidative stress, endothelial 
function, and metabolic profile parameters, in control subjects, determined as Pearson’s 
correlation coefficients (r).  
As regards the nitric oxide metabolic pathway products, the statistical analysis of the data 
pointed out a significant negative correlation, between NOx and the total cholesterol/HDL-
cholesterol ratio, but only in the hyperlipidemic group (Table 2 and 3).  
www.intechopen.com
Oxidized LDL and NO Synthesis as  
Biomarkers of Atherogenesis  Correlations with Metabolic Profile in Elderly 
 
481 
Variables oxLDL 
oxLDL/HDL-C 
ratio 
NOx 
oxLDL/NOx 
ratio 
Hyperlipidemic Group (n = 125) 
Glucose (mg/dL) 0.275** 0.329** 
- 0.096 
(NS) 
0.245** 
Total cholesterol (mg/dL) 0.390** 0.298** - 0.340** 0.437** 
Triglycerides (mg/dL) 0.320** 0.293** 0.037 (NS) 0.128 (NS) 
LDL-cholesterol (mg/dL) 0.377** 0.391** - 0.315** 0.411** 
HDL-cholesterol (mg/dL) - 0.445** - 0.762** 0.011 (NS) - 0.223* 
Total cholesterol/HDL-C 
ratio 
0.578** 0.796** - 0.191* 0.416** 
Atherogenic index (Ai) 0.549** 0.637** 0.054 (NS) 0.220* 
Uric acid(mg/dL) 0.270** 0.201* 0.158 (NS) - 0.006 (NS) 
oxLDL(U/L)  0.895** 
- 0.143 
(NS) 
0.641** 
oxLDL/HDL-C ratio 0.895**  
- 0.111 
(NS) 
0.546** 
NOx (µmol/L) 
- 0.143 
(NS) 
- 0.111 (NS)  - 0.729** 
oxLDL/NOx ratio 0.641** 0.546** - 0.729**  
LDL, low-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; oxLDL, oxidized low-
density lipoprotein; NOx,  nitric oxide metabolic pathway products 
* p < 0.05; ** p < 0.01; NS, non-significant 
Table 3. Interrelationships between studied markers of lipoxidative stress, endothelial 
function, and metabolic profile parameters, in hyperlipidemic subjects, determined as 
Pearson’s correlation coefficients (r) 
To further estimate the extent of oxLDL involvement in endothelial dysfunction, the ratio of 
oxLDL to HDL-cholesterol and the newly introduced ratio of oxLDL to NOx, were 
calculated.  
Significant differences as regards oxLDL/HDL-cholesterol ratio as well as oxLDL/NOx 
ratio were found out between the study groups; both ratios were higher in the 
hyperlipidemic subjects (Table 1).  
Moreover, in the group of subjects with cardiovascular risk, oxLDL/NOx ratio correlated 
significantly with almost each of the traditional parameters of the metabolic profile, namely: 
glycemia, total cholesterol, LDL-cholesterol and HDL-cholesterol, as well as the Ai and 
cardiovascular risk markers (TC/HDL-C and oxLDL/HDL-C ratios) (Table 3). 
We explored the metabolic determinants of oxLDL and NOx by performing the statistical 
multiple correlation test in the whole study population (n=170). Regarding the oxLDL we 
identified significant (p < 0.01) positive correlations with each studied parameters of the 
metabolic profile, such as glycemia (r = 0.351), total cholesterol (r = 0.457), LDL-cholesterol 
(r = 0.456), triglycerides (r = 0.414) and uric acid (r = 0.253). A strong significant negative 
association between oxLDL and HDL-C (r= -0.425, p <0.01) was pointed out. 
In all 170 subjects we pointed out significantly negative correlations (p < 0.01) of NOx levels 
and lipid profile: total cholesterol (r = - 0.470), LDL-C (r = - 0.451), and the atherogenic risk 
marker TC/HDL ratio (r= -0.365) (Figure 2).  
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Fig. 2. Plasma nitric oxide metabolic pathway products (NOx) is inversely correlated with 
total cholesterol/HDL-cholesterol ratio in all the study subjects (n=170) 
Finally, it is important to underscore the most interesting significant, negative, 
correlation, identified between oxLDL and NOx (r = - 0.205, p < 0.01; n = 170) in all study 
population (Figure 3). In the hyperlipidemic group this association was negative but not 
significant. 
The newly introduced ratio oxLDL/NOx was significantly related to the ratio oxLDL/HDL 
(r = 0.547, p < 0.01, n=170), the atherogenic index (Ai) and also the total cholesterol/HDL-
ratio (r = 0.478, p < 0.01 and r = 0.537, p < 0.01) (Figure 4 - A, B, C).   
 
 
Fig. 3. Oxidized LDL (oxLDL) levels are inversely associated with plasma nitric oxide 
metabolic pathway products (NOx) in all the study subjects (n = 170). 
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Fig. 4. oxLDL/NOx ratio is directly correlated with total cholesterol/HDL-cholesterol ratio 
(A), with oxLDL/HDL-cholesterol ratio (B), and with the Atherogenic index (C)  in all the 
study subjects (n=170) 
2.4 Discussion 
The purpose of this work was to point to the interrelationships of oxLDL and NO as 
biomarkers of oxidative stress and endothelial function and the metabolic profile in elderly. 
We explored the literature on molecular mechanisms involved in the biochemical and 
metabolic links of NO and oxLDL. We investigated the metabolic determinants of oxLDL 
and NOx in 170 elderly subjects. Our research results focused mainly on the correlations 
between lipid and lipoprotein parameters as indices of atherogenic risk, and lipoxidative 
stress and endothelial dysfunction biomarkers, namely the nitric oxide metabolic pathway 
products (NOx) and the circulating oxidized LDL.  
Impairment in NO, a common feature in patients with endothelial dysfunction, is 
considered to predict atherosclerosis and cardiovascular events. On the other hand, elevated 
levels of oxidized LDL, formed within the arterial wall, are commonly related to the 
atherogenic profile (Steinberg, 2009; Steinberg & Witzum, 2010). Therefore, in the present 
study, we evaluated the relationships of oxLDL and NOx as oxidative stress and endothelial 
dysfunction biomarkers with the metabolic profile and the cardiovascular high-risk profile 
markers, in 170 elderly patients.  
Plasma NOx levels were significantly lower in patients with hyperlipidemia, further 
suggesting that physiologic levels of NO are necessary to maintain the normal, 
vasodilatatory and noninflammatory phenotype of the vascular wall. A major finding of this 
study is that NO release levels measured by its metabolic pathway products significantly 
A B 
C 
www.intechopen.com
  
Atherogenesis 
 
484 
negatively correlated with circulating oxLDL concentrations. Overall, this work pointed out 
the link between the vascular endothelium vasodilating/vasoconstricting imbalance and the 
metabolic profile in hyperlipidemic elderly patients. 
The evaluations of LDL-cholesterol, high-density lipoprotein-cholesterol, and triglycerides 
are the traditionally recommended lipid screening tests for coronary heart disease (CHD). 
Several studies do suggest that total cholesterol/HDL-cholesterol ratio, a major lipid index, 
is better than the individual total cholesterol, LDL-cholesterol, HDL-cholesterol, and 
triglycerides parameters (Lemieux et al., 2001). This ratio is easily obtained and one of the 
most powerful important risk factors for CHD. Both oxLDL and NOx significantly 
correlated with all markers and calculated atherogenic indices (TC/HDL-C, oxLDL/HDL-C 
and Ai). Hence, our data support the fact that measurements of the oxLDL and NOx levels 
at different times may help to monitor the state and severity of endothelial dysfunction. 
Based on the multiple correlations analysis in both study groups and all subjects we found 
that TC, TC/HDL-C, and oxLDL/HDL-C ratios are major determinants of oxLDL and NO. 
These associations are stronger for the newly introduced oxLDL/NOx ratio. As well, the 
oxLDL/NOx ratio is strongly correlated with the atherogenic index and more importantly, 
with the oxLDL/HDL-C ratio, the best lipid biomarker used for discriminating between 
coronary artery disease patients and healthy control subjects, and also the best blood 
biomarker that reflects atherosclerotic disease activity in the arterial wall (Huang et al., 2008; 
Lankin et al., 2011) 
Our results are in accordance with literature with regard to the damaging effects of 
hyperlipidemia, mediated or stimulated by oxidative stress. Numerous studies have 
supported the role of hyperlipidemia in atherosclerosis, endothelial dysfunction and 
progression of coronary heart diseases (Wallace et al., 2010; Deanfield et al., 2007; 
Highashino et al., 2010; Van den Oever et al., 2010). The hypothesised mechanisms for this 
effect are via hyperlipemia-induced oxidative stress, especially LDL oxidation and 
subsequent reduced NO bioavailibility. The strong significant association of oxidized LDL 
with plasma lipid profile (TC, LDL-C, TG), atherogenic risk markers (TC/HDL-c, 
oxLDL/HDL) and atherogenic index (Ai) found out in the hyperlipidemic group as well as 
the whole population studied, underscore the validity of the observation that hyperlipemia 
induces LDL oxidation and oxidative stress. The oxidative stress generates the superoxide 
radicals (O2.-), which are scavenged by nitric oxide to form peroxynitrite (ONOO-), a 
powerful oxidant. The overproduction of O2.- has direct and indirect effects on vascular NO 
bioavailability. Moreover, O2.- and  ONOO. can oxidize tetrahydrobiopterin (BH4), the 
cofactor necessary for NO production by eNOS enzyme, leading to eNOS uncoupling, and 
thus to more O2.- generation and reduced NO production. Also, the significant negative 
correlation found out in this study between oxLDL and NOx shows that the excess of LDL 
oxidation itself may contribute to reduce NO level. Taken toghether, hyperlipidemia, 
oxidative stress and LDL oxidation result in reduced NO bioavailability via combinatory 
effects of direct elimination and decreased production of NO. This NO reduced 
bioavailability compromises all the antiatherogenic functions of the endothelium. This 
hypothesised mechanism shown above could be a target for interventions to protect against 
hyperlipidemia-induced atherogenesis and cardiovascular disease. 
Based on the strong interrelationships pointed out in this clinical study and the numerous 
experimental and clinical research in the field of atherosclerosis we summarize in figure 5 
the important relationships among hyperlipidemia, oxidative stress, LDL oxidation, nitric 
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oxide and endothelial dysfunction. Hyperlipidemia, oxidative stress and LDL oxidation are 
harmful at multiple steps in atherogenesis, including direct contributions to endothelial 
functions. As shown in figure 5, hyperlipidemia induces enhanced oxidative stress, 
superoxide (O2.-) excessive generation and LDL oxidation. Increased O2.- generation as a 
result of excess mitochondrial lipid oxidation, LDL oxidation and other sources, is critically 
involved in reduced NO bioactivity and endothelial dysfunction, by direct elimination of 
NO.  
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LDL, low-density lipoprotein; oxLDL, oxidized low-density lipoprotein; FFA, free fatty acids; ApoB-
100, apolipoprotein B-100; H2O2, hydrogen peroxide; SOD, superoxide dismutase, ROS, reactive oxygen 
species; HO., hydroxyl radical; LO., alkoxyl radical; LOO., peroxyl radical; ONOO-, peroxynitrite; eNOS, 
endothelial nitric oxide synthase; BH4, tetrahydrobiopterin.  
Fig. 5. Simplified scheme of the interrelationships between oxidative stress, LDL oxidation 
and NO in the hyperlipidemic state leading to endothelial dysfunction. 
There is abundant experimental evidence indicating the role of NO oxidative inactivation as 
a mediator of endothelial dysfunction and a pre-pathogenic vascular phenotype (Harrison, 
1997; Bermudez et al., 2008). The NO is the kinetically preferred scavenger for O2.-, because 
their reaction to generate ONOO- occurs three times faster than the O2.- elimination by 
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superoxide dismutase (SOD) (Beckman & Koppenol, 1996; Cai & Harrison, 2000). Both 
excess generation of reactive oxygen species (ROS) including O2.- and oxidized LDL, and 
decreased antioxidant defence mechanisms  contribute to enhanced degradation  of  NO. 
Many studies support the role of the O2.- as an essential element in the decrease of NO 
bioavailability in oxidative stress conditions. Thus, studies on rabbbits with aortic 
atherosclerosis, demonstrated a remarkable decrease in endothelium-related relaxation, 
which was corrected by SOD treatment (Dulak et al., 1997). 
Also, peroxynitrite is itself a powerful oxidant which contributes to enhance oxidative 
stress and turn the balance NO - ROS in the favour of ROS. Both radicals, O2.- and ONOO- 
can oxidize tetrahydrobiopterin (BH4) leads to eNOS uncoupling, which in turn will 
produce O2.- instead of NO, and activate this vicious cycle (Fostermann, 2006). 
Uncoupling eNOS directly leading to decreased NO production. Not only BH4 oxidation, 
but also decreases in BH4 concentrations may reduce the NO production. Thus, many 
studies have shown a significant decrease in BH4 activity in various pathological states, 
such as: hyperlipidemia, hypercholesterolemia, insulin resistance, probably through the 
oxLDL increase, as well as increased expression in some proinflammatory cytokine (TNF-
alpha, interleukin-1 beta) (Bowers et al., 2011; Wever et al., 1997; Stroes et al., 1997). 
Furthermore, clinical and experimental studies have confirmed these mechanisms, 
showing that acute administration of BH4 improve the endothelial dysfunctions related to 
hyperlipidemia, atherosclerosis and hypertension (Setoguchi et al., 2001). Also, a decrease 
in arginine and consequently a lack in eNOS substrate bioavailability leads to a failure in 
NO synthesis (Bermudez et al, 2005). 
Recent in vitro studies (Bowers et al., 2011) demonstrated that tetrahydrobiopterin (BH4) 
could reduce oxLDL-induced O2.- production by NADPH oxidase, increasing NO synthesis 
in endothelial cells. The superoxide anion production was increased by pretreatment of cells 
with an inhibitor of BH4 synthesis, and decreased following pretreatment with a BH4 
precursor. Thus, BH4 concentrations can modulate the NADPH oxidase-induced imbalance 
of endothelial NO and O2.- production. BH4 may be critical in combating oxidative stress, 
restoring proper redox state and reducing risk for cardiovascular disease including 
atherosclerosis. 
Other mechanisms are also involved in the interrelations of LDL oxidation, nitric oxide and 
endothelial dysfunction. The oxidized LDL may reduce eNOS levels by inhibiting eNOS 
gene expression (Dulak et al., 1997) and also can displace eNOS from caveolae by binding to 
endothelial cell CD36 receptors and by depleting caveolae cholesterol content and therefore 
disrupt eNOS activity (Barbato et al., 2004). These adverse effects of oxLDL are prevented by 
HDL via binding to scavenger receptor BI (SR-BI), colocalized with eNOS in endothelial 
caveolae. This occurs through the maintenance of caveolae cholesterol content by cholesterol 
ester uptake from HDL. Moreover, HDL binding to SR-BI may stimulate eNOS activity in 
endothelial cells, and enhance endothelium- and NO-dependent relaxation. Thus, 
lipoproteins have potent effects on eNOS function in caveolae via actions on both membrane 
cholesterol homeostasis and the level of activation of the enzyme, processes that may be 
critically involved in the earliest phases of atherogenesis (Rigotti et al., 1997; 
Uittenbogaraard et al., 2000; Yuhanna et al., 2001; Schaul, 2003). The significant negative 
correlations between HDL and oxLDL, oxLDL/HDL ratio, atherogenic index and more 
important oxLDL/NO ratio pointed out in hyperlipidemic group and all subjects, 
underscore the beneficial effect of HDL on the endothelium. 
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Recent studies demonstrated that oxLDL causes impairment of endothelium-dependent, 
nitric oxide-mediated vasodilation involving L-arginine deficiency. The oxLDL may reduce 
L-arginine availability to eNOS for NO production, by up-regulating arginase. The 
experimental studies indicated that oxLDL increased arginase expression in the vascular 
wall without altering eNOS expression (Wang et al., 2011). 
Experimental studies underscore the dual role of oxLDL on endothelial cells causing either 
proliferation or apoptosis, depending on its concentration and exposure time (Galle et al., 
2001). Thus, oxLDL induced proliferation at low (5 to 10 microg/mL) and apoptosis at 
higher concentrations (50 to 300 microg/mL). Both effects are mediated by O2.- formation via 
NADPH oxidase as it major source. Thus, oxLDL contributes importantly to vascular 
cellular turnover through the induction of oxidative stress. More recently, was 
demonstrated that oxLDL at low concentrations (5 microg/mL) promotes in vitro 
angiogenesis and activate nitric oxide synthase through Pl3K/Akt/eNOS pathway in 
human coronary artery endothelial cells (Yu et al., 2011). 
On the whole, the decline in nitric oxide bioavailability is caused by the cummulative effects 
of many factors and processes discussed above: the decreased expression of the endothelial 
NO synthase, a reduction of substrate or cofactors for eNOS, alterations of cellular signaling, 
eNOS inhibition by asymmetric demethyl arginine, reduced NO production and accelerated 
NO degradation by hyperlipidemia, oxidative stress and LDL oxidation.  
Taking into account overall the atherogenic properties of oxidized LDL, involved in all 
stages of atherosclerosis (Steinberg et al., 1989; Steinberg, 2009), and the vasoprotective and 
antioxidant functions of NO (Bermudez et al., 2008; Yasa & Turkseven, 2005), we introduced 
for the first time the ratio oxLDL to NOx for quantifying their possible cumulative effect on 
vascular endothelium. The strong positive associations of this ratio with the atherogenic 
index and the atherogenic risk markers: TC/HDL and oxLDL/HDL ratios, supported us to 
propose this newly introduced ratio (oxLDL/NOx) as a potential marker of endothelial 
dysfunction. The future in depth studies, will take into consideration the association with 
clinical parameters of vascular endothelial functions using acethylcholine to induce 
endothelium dependent dilation, quantitative angiography, and high resolution ultrasound 
to measure brachial artery diameter, to further support this new candidate marker. 
Wu et al., (2006) suggested in a prospective cohort study that circulating oxLDL as an 
individual parameter, measured with antibody 4E6, was not an independent overall 
predictor of coronary heart disease (CHD), after adjustment of lipid markers and less 
predictive in development of CHD than apoB and total cholesterol/HDL-cholesterol ratio 
(Wu et al., 2006). Therefore, based on the results obtained in our study it is important to 
examine in future research whether the ratio oxLDL to NOx correlates with endothelial 
function and predicts CHD independently of the lipid markers.  
Data of this study support the relevance of oxLDL and NOx as biomarkers reflecting, at 
systemic level, the progressive damage at cellular level under the action of prooxidant 
pathogenic factors. These biomarkers could be valuable in the complex evaluation of 
oxidative stress in the endothelium. 
Despite numerous evidences of oxidative processes involved in atherosclerosis and the 
multiple experimental research on their inhibition by traditional antioxidants, and the 
success in several animal trials, the human clinical trials using antioxidants have failed 
(Parthasarathy et al., 2008; da Luz et al., 2006). There were not taken into consideration all 
the factors, aspects, processes, steps and stages involved in early or advanced atherosclerotic 
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lesions, their interrelations, and the most important the pro-oxidant properties and actions 
of antioxidants in different oxidative process steps and disease stages. 
These interrelatioships pointed out in our study could be very important in the management 
of new effective therapeutic strategies for atherosclerosis and cardiovascular disease. 
Because oxidative stress, LDL oxidation and endothelial dysfunction centrally contributes to 
cardiovascular disease, further sustained efforts must be undertaken to translate this 
knowledge into the characterization and identification of biomarkers that enable preventive 
or early detection of injuries and allow improved risk stratification by integration into 
cardiovascular risk stratification models.  
2.5 Limitations of our study 
The study population included only elderly and therefore the results may be different in 
other age-groups subjects, in order to have identified the early onset of hyperlipidemia-
induced vascular impairment. Another important limitation was that we did not evaluate 
the endothelial function using the flow-mediated dilation (FMD) and ultrasound 
examination of the right brachial artery.  
3. Conclusion 
The results of this correlations study pointed out that in hyperlipidemic elderly patients the 
endothelial NO synthesis could indeed be impaired and associated with a higher oxidative 
stress exerted on circulating LDL particles. Oxidized LDL has a large range of biological 
effects that contribute to atherogenesis, but NO also has many biological effects that prevent 
atherogenesis. In this context, the interrelations pointed out between hyperlipidemia, 
oxidative stress, LDL oxidation and nitric oxide leading to endothelial dysfunctions, 
emphasized their implications in molecular mechanisms of endothelial dysfunction.  
It is important to distinguish between the effect of oxidized LDL and the effect of a 
deficiency in the release of NO and to draw a link between these two biomarkers. According 
to the results obtained in this study, we propose the use of a new marker of endothelial 
dysfunction, the ratio of oxLDL to NOx, which could be a more accurate estimation of the in 
vivo cumulative implications of oxLDL and NO in atherogenesis. Future studies taking into 
account the association of this newly introduced marker with other markers of endothelial 
function will be undertaken to support the marker validity. 
The strong interrelations pointed out in our study underscore the molecular mechanisms 
implicated in endothelial dysfunctions and atherosclerosis presented in this chapter. Future 
research is needed to translate this knowledge into the identification, characterization and 
validation of new and known biomarkers of lipoxidative stress-induced endothelial 
dysfunctions and atherosclerosis, and their integration into cardiovascular risk 
stratifications models. 
These findings suggest the importance of understanding the senescent specific changes 
occurring in endothelium associated with age-related disease. Such an understanding may 
not only provide answers regarding mechanisms of disease development, but may also 
provide biomarkers of endothelium specific ageing.  
As perspectives, the nutritional and therapeutic strategies should attempt to correct the lipid 
profile and lipoxidative stress in order to prevent the amplification of redox and 
inflammatory phenomena that lead to increased cardiovascular risk. As well, therapeutic 
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approaches in the prevention and treatment of atherosclerosis based on improving NO 
bioactivity and reducing LDL oxidation may become a challenge for future studies. 
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